Physician profile
Kevin E Rosas
NPI 1013979590
$6,330.13
in general payments reported to CMS, 2019-2025
10 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,834 · 2020: $706 · 2021: $76.61 · 2022: $61.21 · 2023: $1,202 · 2024: $1,111 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,724 · Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,723.64 |
| Food and Beverage | $928.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $3,079.80 | 2019-2024 | |
| Prodigy Surgical Distribution, INC. | $2,383.60 | 2019-2025 | |
| Stryker Corporation | $357.09 | 2019-2024 | Inbone |
| Depuy Synthes Sales INC. | $187.35 | 2019-2024 | Inhance |
| Zimmer Biomet Holdings, INC. | $108.82 | 2025 | A.L.P.S. |
| Ferring Pharmaceuticals INC. | $93.35 | 2019-2023 | Euflexxa |
| Treace Medical Concepts, INC. | $61.87 | 2023-2024 | |
| Vertex Pharmaceuticals Incorporated | $29.91 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $17.44 | 2022 | |
| Vericel Corporation | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Rosas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.